Alessandro Inno

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Alessio Cortellini, Marco Tucci, Vincenzo Adamo et al. · Journal for ImmunoTherapy of Cancer · 2020 · 250 citations · Full text

PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections

Enrico Munari, Giuseppe Zamboni, Gianluigi Lunardi et al. · Journal of Thoracic Oncology · 2018 · 173 citations · Full text

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Alessio Cortellini, Massimo Di Maïo, Olga Nigro et al. · Journal for ImmunoTherapy of Cancer · 2021 · 132 citations · Full text

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

Alessio Cortellini, Biagio Ricciuti, Marcello Tiseo et al. · Journal for ImmunoTherapy of Cancer · 2020 · 95 citations · Full text

Contribution of <i>KRAS</i> mutations and c.2369C &gt; T (p.T790M) <i>EGFR</i> to acquired resistance to EGFR-TKIs in <i>EGFR</i> mutant NSCLC: a study on circulating tumor DNA

Marzia Del Re, Marcello Tiseo, Paola Bordi et al. · Oncotarget · 2016 · 84 citations · Full text